相关实验视频

Updated: May 2, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

在非小细胞肺癌中系统性免疫炎症指数的进展:一篇综述

Kai-Yun Mao¹, Yuan-Chao Cao¹, Mao-Yan Si²

¹First Clinical Medical College, Gannan Medical University, Ganzhou, China.

|May 3, 2024

概括

系统性免疫炎症指数 (SII) 反映了炎症和免疫状态. 本综述探讨了它对非小细胞肺癌发展,进展和预后的影响.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
炎症研究的研究.

背景情况:

非小细胞肺癌 (NSCLC) 是全球癌症死亡的主要原因.
炎症越来越被认为是癌症发展,进展和患者结果的关键因素.
系统性免疫炎症指数 (SII) 来自中性粒细胞,淋巴细胞和血小板数量,为系统性炎症和免疫反应提供了全面的衡量标准.

研究的目的:

审查当前关于系统性免疫炎症指数 (SII) 在非小细胞肺癌 (NSCLC) 中的作用的文献.
阐明SII对NSCLC发育,进展和预后的影响.
突出SII作为一个具有成本效益和非侵入性的生物标志物的临床实用性.

主要方法:

对调查SII和NSCLC之间关联的研究的文献综述.
对与癌症发病率,瘤特征和患者存活率相关联的SII水平数据的分析.
关于NSCLC中SII的预测和预后价值的发现综合.

主要成果:

升高的SII水平经常与NSCLC的风险增加和预后较差有关.
SII已经显示出作为治疗反应和生存结果的预测生物标志物的潜力.
该指数整合了与癌症生物学相关的关键炎症和免疫细胞组件.

结论:

系统性免疫炎症指数 (SII) 是评估NSCLC患者炎症和免疫状况的有价值和可访问的生物标志物.
SII具有改善风险分层,预测预后和指导非小细胞肺癌治疗策略的巨大潜力.
需要进一步的研究,才能将SII完全整合到NSCLC管理的临床实践中.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...